Adding clinical value with coronary flow assessment in hypertrophic obstructive cardiomyopathy - PubMed (original) (raw)

Editorial

Adding clinical value with coronary flow assessment in hypertrophic obstructive cardiomyopathy

Thomas H Schindler et al. Int J Cardiol Heart Vasc. 2020.

No abstract available

Keywords: Cardiac magnetic resonance imaging; Cardiovascular risk; Flow gradient; Hypertrophic cardiomyopathy; Myocardial blood flow; Myocardial flow reserve; Positron emission tomography.

PubMed Disclaimer

Comment on

• Hypertrophic cardiomyopathy.
  Antunes MO, Scudeler TL. Antunes MO, et al. Int J Cardiol Heart Vasc. 2020 Mar 25;27:100503. doi: 10.1016/j.ijcha.2020.100503. eCollection 2020 Apr. Int J Cardiol Heart Vasc. 2020. PMID: 32309534 Free PMC article. Review.

References

1. 1. Veselka J., Anavekar N.S., Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389:1253–1267. -PubMed
2. 1. Poli S., Facchin D., Rizetto F. Prognostic role of non-sustained ventricular tachycardia detected with remote interrogation in a pacemaker population. Int. J. Cardiol. Heart. Vasc. 2019;22:92–95. -PMC -PubMed
3. 1. Valenta I., Szabo Z., Mathews W.B., Abraham T.P., Abraham M.R., Schindler T.H. PET/CT imaging of cardiac angiotensin II Type 1 receptors in nonobstructive hypertrophic cardiomyopathy. JACC Cardiovasc. Imaging. 2019;12:1895–1896. -PubMed
4. 1. Bravo P.E., Zimmermann S.L., Luo H.C. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ. Cardiovasc. Imaging. 2013;6:210–217. -PMC -PubMed
5. 1. Ogano M., Iwasaki Y.K., Tsuboi I. Mid-term feasibility and safety of downgrade procedure from defibrillator to pacemaker with cardiac resynchronization therapy. Int. J. Cardiol. Heart. Vasc. 2019;22:78–81. -PMC -PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PMC
  • PubMed Central